Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07287943 · ClinicalTrials.gov registry record · NA
To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.
A NA study of Type 1 Diabetes and Gastroparesis Due to Diabetes Mellitus Type I, sponsored by Viral N. Shah.
- Recruiting
- Registry status
- NA
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT07287943: Recruiting NA study of Type 1 Diabetes and Gastroparesis Due to Diabetes Mellitus Type I, sponsored by Viral N. Shah.
NCT07287943 is a NA study of Type 1 Diabetes and Gastroparesis Due to Diabetes Mellitus Type I that is actively recruiting participants, run by Viral N. Shah. The registered enrollment target is 34 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07287943, a NA study of Type 1 Diabetes and Gastroparesis Due to Diabetes Mellitus Type I, is actively recruiting participants, sponsored by Viral N. Shah.
- RECRUITING
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the efficacy and safety of Medtronic 780G automated insulin delivery system in adult persons with type 1 diabetes and gastroparesis.
Primary Outcome
Percentage of time that sensor glucose values are within the target range of 70-180 mg/dL, as measured by continuous glucose monitoring (CGM).
Conditions Studied
Interventions
- DEVICE Medtronic 780G AID
Study Locations (1)
Indiana
- Indiana University Health, Univeristy hospital - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2026-12-01 |
| Phase | NA |
What NCT07287943 shows while recruiting
NCT07287943 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Medtronic 780G AID is the first listed.
NCT07287943 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT07287943 about?
NCT07287943 is a clinical study titled "To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.". The goal of this clinical trial is to evaluate the efficacy and safety of Medtronic 780G automated insulin delivery system in adult persons with type 1 diabetes and gastroparesis.
What is the current status of trial NCT07287943?
This trial is currently recruiting. It is a NA study. The enrollment target is 34 participants. The study started on 2026-02-09. Estimated completion is 2026-12-01.
What conditions does trial NCT07287943 study?
This clinical trial studies the following conditions: Type 1 Diabetes, Gastroparesis Due to Diabetes Mellitus Type I.
What interventions are being tested in trial NCT07287943?
The interventions under investigation include: Medtronic 780G AID (DEVICE).
Who is sponsoring clinical trial NCT07287943?
This trial is sponsored by Viral N. Shah, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07287943 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07287943's enrollment target sits among peer trials
34 118th of 198 higher than 79 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
REAL-Fam Feasibility Study for Youth Diabetes Management
RECRUITING · NA
-
AIDANET Pediatrics
RECRUITING · NA
-
A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes
RECRUITING · NA
-
Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery
RECRUITING · NA
-
EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes
RECRUITING · NA
-
Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI